Evidence Hub

Updates in Cystic Fibrosis Bone Disease in Adults

Runchey S, Harindhanavudhi T, Wu M, Tangpricha V

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2026

Abstract

Objective: To summarize current understanding of cystic fibrosis-related bone disease (CFBD), including its pathophysiology, epidemiology, screening recommendations and management in adults, and to highlight knowledge gaps and research priorities in the era of highly effective CFTR modulator therapy.

Methods: A narrative review of the existing literature on CFBD, encompassing the pathophysiology, epidemiologic data, clinical guidelines for screening and fracture risk assessment, and evidence supporting pharmacologic and non-pharmacologic treatments in adults with CFBD.

Results: Cystic fibrosis (CF) is a multisystem autosomal recessive disease caused by variants of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. As survival improves with modulator therapy, CFBD has become an increasingly prevalent complication. Its pathogenesis is multifactorial, due to intrinsic CFTR dysfunction in bone compounded by malnutrition, vitamin deficiencies, chronic inflammation, CF-related diabetes, hypogonadism, and exposure to high-risk medications. Up to two-thirds of adults over 45 years have low bone density, conferring a 2-10-fold higher fragility fracture risk. Current guidelines recommend routine dual-energy x-ray absorptiometry, vertebral fracture assessment, and laboratory evaluation, with individualized bone therapy. Nonpharmacologic therapy includes nutritional optimization, physical activity, and modification of risk factors. Pharmacologic management, including…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free